EGFR and non-small cell lung carcinoma: Clinically approved EGFR inhibitors for NSCLC treatment include the first-generation competitive inhibitors, such as erlotinib and gefitinib, the second-generation irreversible pan-ERBB family inhibitors, such as afatinib and dacomitinib, and the third-generation mutation-specific inhibitors, such as osimertinib and lazertinib.